statnews.com·May 14, 2026
CREATE Medicines, formerly known as Myeloid Therapeutics, has rebranded and expanded its research pipeline to include CAR-T therapies for both cancer and autoimmune diseases, securing $122 million in funding to advance its first human trials.
CREATE Medicines' recent $122 million funding round, backed by notable investors like Newpath Partners and ARCH Venture Partners, positions the company to advance its innovative CAR-T therapies targeting solid tumors and autoimmune diseases. This signals a strong investment opportunity in the expanding CAR-T space, particularly for those focused on novel applications beyond oncology.